Recent publications

• Low-dose Buprenorphine Initiation in Pregnancy: A Systematic Review July 17, 2025
  CONCLUSIONS: Reports of LDBI in pregnant patients are emerging. While some level of withdrawal appears to be frequent, few studies reported precipitated withdrawal, and findings align with LDBI outcomes seen in nonpregnant patients. It is unknown how selection and/or reporting bias impact findings, and prospective, randomized, controlled trials are needed.
  Kyle A Grenier
• Building Implementation Science Capacity in Academic Pharmacy: Report of the 2020-2021 AACP Research and Graduate Affairs Committee July 17, 2025
  The 2020-2021 AACP Research and Graduate Affairs Committee (RGAC) continued the work begun by the 2019-2020 RGAC to increase awareness of and capacity for implementation research to advance practice transformation in academic pharmacy. AACP President Anne Lin charged the RGAC with developing resources and programs for training faculty and graduate students in implementation science. The […]
  Kimberly B Garza
• Culturally Specific Trauma History is Associated with Dietary Intake Outcomes of a Healthy Eating Intervention Among Cambodian American Refugees: A Retrospective Cohort Study July 5, 2025
  CONCLUSIONS AND IMPLICATIONS: Eat, Walk, Sleep was most beneficial for those with certain trauma characteristics. Future work includes investigation of potential mechanisms of action of Eat, Walk, Sleep, such as self-efficacy and peer support.
  Julie A Wagner
• Routine invasive vs. conservative strategy in elderly patients with non-ST-elevation acute coronary syndrome July 3, 2025
  CONCLUSIONS: In elderly NSTE-ACS patients, routine invasive strategy reduces cardiovascular events without significantly increasing bleeding, supporting individualized treatment decisions.
  Carlos Diaz-Arocutipa
• A Descriptive Assessment of Products Containing the Opioid Receptor Stimulator Mitragynine Pseudoindoxyl June 26, 2025
  Background: Potent semi-synthetic alkaloids that stimulate opioid receptors are being sold to consumers in gas stations, smoke shops, and online as the dietary supplement 'kratom'. Objective: We descriptively evaluated the characteristics of products containing mitragynine pseudoindoxyl. Results: Fifty-one unique products met our inclusion criteria. Seventy-one percent of products contained mitragynine pseudoindoxyl plus 7-hydroxymitragynine, 24% contained […]
  C Michael White
• Pediatric Antibiotic Stewardship Programs: The Path Forward June 19, 2025
  Antibiotic overuse has been well-documented in all populations, including pediatrics. Pediatric pharmacists are valuable and well-integrated within inpatient antibiotic stewardship programs (ASP) in children's hospitals. The Pediatric Pharmacy Association (PPA) believes all pharmacists, regardless of practice setting, should receive education to support entry-level stewardship activities in pediatric patients. Additionally, pediatric antibiotic stewardship pharmacist leaders should […]
  Jennifer E Girotto
• Sex differences on cerebrovascular complications in hospitalized COVID-19 patients: a meta-analysis June 15, 2025
  CONCLUSIONS: This is the first meta-analysis to stratify stroke risk by sex and stroke subtype in hospitalized COVID-19 patients. Males were at significantly higher risk for hemorrhagic stroke, suggesting possible sex-specific vulnerability that warrants further studies.
  Bradley Ong
• Managing ciprofloxacin-clozapine interaction with immunoassay-based monitoring: A case report June 11, 2025
  Whereas the interaction between clozapine and ciprofloxacin is well-documented, this case report emphasizes the importance of closely monitoring clozapine plasma concentrations during concurrent administration. When available, clozapine concentrations may be obtained via immunoassay to assess clozapine concentrations more quickly and subsequently adjust clozapine doses. Frequent monitoring is especially important for guiding appropriate dose adjustments in […]
  Kristin Waters
• Elizabethkingia meningoseptica: Case report on an emerging pathogen and its associated treatment challenges June 9, 2025
  Elizabethkingia meningoseptica is a Gram-negative bacillus that was previously thought to rarely infect humans but recently has been identified as an emerging pathogen in both community and nosocomial settings. Typically found in the environment, this organism has been shown to infect predisposed hosts with an immunocompromised status and/or a prolonged exposure to healthcare settings. Herein, […]
  Fabrizio Tropea
• Outcomes in New User Cohorts of SGLT2 Inhibitors or GLP-1 Receptor Agonists with Type 2 Diabetes and Chronic Kidney Disease June 4, 2025
  CONCLUSION: Understanding the incidence of kidney failure and cardiovascular outcomes in people receiving antidiabetic medications with cardiorenal protective effects is important for future studies aiming to compare the incidence of kidney and cardiovascular outcomes related to new and existing CKD treatments.
  J Bradley Layton
• Believing FDA's Assurance of Quality Pharmaceutical Products Can Be Dangerous to Your Patients' Health June 3, 2025
  The Food and Drug Administration (FDA) exists to protect US consumers. However, while drug manufacturing has shifted dramatically to developing countries like India and China, the FDA first silently followed a "trust and not verify" strategy with virtually no overseas inspections until overwhelming evidence of patient harm had occurred. The implementation of the Generic Drug […]
  C Michael White
• Preparing NAPLEX-Ready Graduates Requires Collaboration to Optimize Success June 2, 2025
  Declining NAPLEX pass rates are prompting widespread discussions and urgent investigations into potential causes, including an examination of PharmD program characteristics, curriculum, student preparedness, and an evolving exam blueprint. Many studies have been conducted to understand the association of various factors with NAPLEX success, and individual programs have attempted to address these factors with mixed […]
  Mary Elizabeth Ray
• Generic Versus Brand-Name Immunosuppression Following Heart Transplant: An Analysis of the UNOS Database June 1, 2025
  CONCLUSION: Despite initial differences in unadjusted outcomes, adjusted analyses did not demonstrate a significant difference in graft failure or mortality between brand-name and generic immunosuppressant regimens. These findings suggest that clinicians can confidently prescribe generic immunosuppressants without compromising patient outcomes, potentially leading to substantial healthcare savings.
  Aviral Mahajan
• Effects of Sacubitril/Valsartan on Renal Function in Adults With Heart Failure: A Systematic Review and Meta-Analysis of Randomised Controlled Trials June 1, 2025
  CONCLUSIONS: In adults with HF, S/V likely reduced doubling sCr compared to ACEI or ARB but may have little to no effect on WDRF, a >50% decline in eGFR, and hyperkalaemia.
  Joshuan J Barboza
• Clinical evaluation of zavegepant for the acute treatment of migraine May 30, 2025
  Zavegepant is the first intranasal calcitonin gene-related peptide receptor antagonist approved for the acute treatment of migraine and offers a new nonoral option for patients. This article reports the findings of a comprehensive literature review to assess zavegepant's safety and effectiveness. Evidence synthesis involved reporting findings from clinical trials and evaluating comparative effectiveness. This review […]
  Huiqiao Fan
• Re: Optimizing the handling of missing data in the UNOS database May 28, 2025
  No abstract
  William L Baker
• Efficacy and harms associated with β-blockers for cardiotoxicity in cancer patients undergoing chemotherapy: a systematic review and meta-analysis May 21, 2025
  CONCLUSIONS: Prophylactic use of β-blockers for cardioprotection had little to no effect on all-cause mortality, LVEF or cardiac function outcomes in cancer patients undergoing anthracycline therapy.
  Jessica T Li
• An External Control Arm for the Oral Factor XIa Inhibitor Asundexian Phase 2 Trial in Atrial Fibrillation (PACIFIC-AF) Using Electronic Health Records May 16, 2025
  CONCLUSIONS: ECAs matching the PACIFIC-AF apixaban arm could be built from EHRs with concordant event rates for key trial endpoints. The ECA approach enabled the determination of event rates for treatment duration up to 2 years, thereby informing the asundexian pivotal phase 3 trial in AF.
  Tatsiana Vaitsiakhovich
• Improved oral anticancer medication (OAM) adherence/toxicity assessment documentation: A quality improvement initiative May 13, 2025
  IntroductionAdherence and toxicity symptoms ideally are monitored within 7-14 days after initiating oral anticancer medication (OAM). After implementing a formal OAM program at our institution, we found our adherence and toxicity monitoring was suboptimal and sought to improve our processes to reduce patient risk, using a formal quality improvement methodology.Patient and methodsAdult patients with a […]
  Lisa M Holle
• Comparative efficacy and safety of SGLT2 inhibitor class members in patients with heart failure and type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials May 5, 2025
  We conducted a systematic review with pairwise (PMA) and network meta-analyses (NMA) to evaluate sodium-glucose transport protein 2 inhibitor (SGLT2i) effects in patients with both heart failure (HF) and type 2 diabetes mellitus (T2DM). Five databases were searched up to April 15, 2025. Primary outcomes were all-cause mortality (ACM), cardiovascular death (CVD), all-cause hospitalization (ACH), […]
  Angela Y Su